
Conference Coverage EHA 2022 – Focus on Multiple Myeloma
The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?
Faculty Members
TBC
REPORT TOPICS
- First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma
- First Line (2): Induction in Transplant-Eligible Multiple Myeloma
- First Line (3): Maintenance and MRD
- Relapsed/Refractory Multiple Myeloma: First and Second Relapse
- Relapsed/Refractory Multiple Myeloma: Novel Agents
- Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics
- Relapsed/Refractory Multiple Myeloma: CAR Ts